← Leaderboards
Adriana Hung
Vanderbilt University
$417,520
Attributed
$417,520
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $225.6K · FY2007–25$250K$187.5K$125K$62.5K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$417,520 · 1
VA$0 · 3
By mechanism
R21$417,520 · 1
I01$0 · 3
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Nancy Joan Brown$32,445,188
- Kathleen M Egan$9,897,730
- Carolyn Heinrich$1,165,288
- Hassane S McHaourab$22,963,634
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventRisk FactorsPharmaceutical PreparationsAffectEnd Stage Renal FailureChronic Kidney FailureHypertensionCaringPrevalencePrematureCessation Of LifeMissionCardiovascular DiseasesDiabetes MellitusVeteransLinkProgramsGenetic VariantGeneticVariantKidney DiseasesDisease ProgressionGenome Wide Association StudyGlomerular Filtration Rate
Grant awards (16)
Genetic of Kidney Disease and Hypertension in MVP II$0
I01 · FY2025 · VA · contact PI
Genetics of CKD and Hypertension-Risk Prediction and Drug Response in the MVP$0
I01 · FY2024 · VA · contact PI
Genetics of CKD and Hypertension-Risk Prediction and Drug Response in the MVP$0
I01 · FY2023 · VA · contact PI
Genetics of CKD and Hypertension-Risk Prediction and Drug Response in the MVP$0
I01 · FY2022 · VA · contact PI
Genetics of CKD and Hypertension-Risk Prediction and Drug Response in the MVP$0
I01 · FY2021 · VA · contact PI
Genetics of CKD and Hypertension-Risk Prediction and Drug Response in the MVP$0
I01 · FY2020 · VA · contact PI
Pharmacogenomics of risk factors and therapies outcomes for kidney disease$0
I01 · FY2020 · VA · contact PI
Pharmacogenomics of risk factors and therapies outcomes for kidney disease$0
I01 · FY2019 · VA · contact PI
Pharmacogenomics of risk factors and therapies outcomes for kidney disease$0
I01 · FY2018 · VA · contact PI
Dysmetabolism of Chronic Kidney Disease and Vascular Health$0
I01 · FY2018 · VA · contact PI
Dysmetabolism of Chronic Kidney Disease and Vascular Health$0
I01 · FY2017 · VA · contact PI
Pharmacogenomics of risk factors and therapies outcomes for kidney disease$0
I01 · FY2017 · VA · contact PI
Dysmetabolism of Chronic Kidney Disease and Vascular Health$0
I01 · FY2016 · VA · contact PI
Dysmetabolism of Chronic Kidney Disease and Vascular Health$0
I01 · FY2015 · VA · contact PI
Inflammation, proteolysis and IL-1beta receptor inhibition in CHD patients$225,645
R21 · FY2008 · DK · contact PI
Inflammation, proteolysis and IL-1beta receptor inhibition in CHD patients$191,875
R21 · FY2007 · DK · contact PI